EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis

Akira Kuwabara iD, Kazuhide Inage iD, Masaomi Yamashita iD, Sumihisa Orita iD, Yawara Eguchi iD, Yasuhiro Shiga iD, Masahiro Inoue iD, Miyako Suzuki-Narita iD, Takahisa Hishiya iD, Kohei Okuyama iD, Susumu Tashiro iD, Shuhei Ohyama iD und 4 weitere

Yonsei Medical Journal · 2026 · 67 (9) · 680

DOI: 10.3349/ymj.2025.0262 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Yonsei Medical Journal, 2026. Verfasst von Akira Kuwabara und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan. Hauptthemen laut MEDLINE: Denosumab, Osteoporosis, Antibodies, Monoclonal, Bone Density Conservation Agents. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DenosumabOsteoporosisAntibodies, MonoclonalBone Density Conservation AgentsHumansFemaleRetrospective StudiesBone DensityAgedMaleMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Romosozumabbone densitydenosumabosteoporosis

Substanzen

DenosumabAntibodies, MonoclonalromosozumabBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Rehabilitation, JCHO Funabashi Central Hospital, Funabashi, Japan. debitrosi@gmail.com.
  • Department of Orthopaedic Surgery, JCHO Funabashi Central Hospital, Funabashi, Japan.
  • Center for Frontier Medical Engineering, Chiba University, Chiba, Japan.
  • Department of Bioenvironmental Medicine, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Department of Rehabilitation, JCHO Funabashi Central Hospital, Funabashi, Japan.

ORCID-Profile: Akira Kuwabara, Kazuhide Inage, Masaomi Yamashita, Sumihisa Orita, Yawara Eguchi, Yasuhiro Shiga, Masahiro Inoue, Miyako Suzuki-Narita, Takahisa Hishiya, Kohei Okuyama, Susumu Tashiro, Shuhei Ohyama, Noritaka Suzuki, Akihiro Iida, Yu Otake, Seiji Ohtori

Zitieren

APA

Kuwabara, A., Inage, K., Yamashita, M., Orita, S., Eguchi, Y., Shiga, Y., Inoue, M., Suzuki-Narita, M., Hishiya, T., Okuyama, K., Tashiro, S., Ohyama, S., Suzuki, N., Iida, A., Otake, Y., & Ohtori, S. (2026). Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis. Yonsei Medical Journal, 67(9), 680. https://doi.org/10.3349/ymj.2025.0262

Vancouver

Kuwabara A, Inage K, Yamashita M, Orita S, Eguchi Y, Shiga Y, et al. Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis. Yonsei Medical Journal. 2026;67(9):680. doi:10.3349/ymj.2025.0262

BibTeX
@article{Kuwabara2026,
  author = {Kuwabara, Akira and Inage, Kazuhide and Yamashita, Masaomi and Orita, Sumihisa and Eguchi, Yawara and Shiga, Yasuhiro and Inoue, Masahiro and Suzuki-Narita, Miyako and Hishiya, Takahisa and Okuyama, Kohei and Tashiro, Susumu and Ohyama, Shuhei and Suzuki, Noritaka and Iida, Akihiro and Otake, Yu and Ohtori, Seiji},
  title = {Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab–Denosumab Therapy for Severe Osteoporosis},
  journal = {Yonsei Medical Journal},
  year = {2026},
  volume = {67},
  number = {9},
  pages = {680},
  doi = {10.3349/ymj.2025.0262}
}
Kostenlos starten →